Glimepiride is recognized in several major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These monographs provide comprehensive specifications to ensure the quality, purity, and efficacy of Glimepiride.
The USP monograph for Glimepiride Tablets includes specific dissolution tests to assess the drug's release profile. For example, the revision bulletin dated November 24, 2010, introduced additional dissolution tests to accommodate generic products approved by the FDA.
Purity and assay requirements are stringent across these pharmacopoeias, typically mandating a purity of not less than 99.0% and specifying limits for related substances to control impurities. Dissolution testing is crucial to ensure consistent bioavailability; the USP specifies that Glimepiride tablets should release not less than 75% of the labeled amount within 45 minutes.
Stability testing for Glimepiride is conducted in accordance with the International Council for Harmonisation (ICH) guidelines, which define different climatic zones to account for global variations. For instance, ICH Zone IV, which includes countries with hot and humid climates, requires stability studies at 30ยฐC and 75% relative humidity to ensure the drug's efficacy over its shelf life.
Adherence to these pharmacopoeial standards and ICH guidelines is essential for manufacturers to ensure the safety, efficacy, and quality of Glimepiride products in the global market.